Cargando…
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
The MYC oncogene is upregulated in human cancers by translocation, amplification, and mutation of cellular pathways that regulate Myc. Myc/Max heterodimers bind to E box sequences in the promoter regions of genes and activate transcription. The MYC inhibitor Omomyc can reduce the ability of MYC to b...
Autores principales: | Demma, Mark J., Mapelli, Claudio, Sun, Angie, Bodea, Smaranda, Ruprecht, Benjamin, Javaid, Sarah, Wiswell, Derek, Muise, Eric, Chen, Shiying, Zelina, John, Orvieto, Federica, Santoprete, Alessia, Altezza, Simona, Tucci, Federica, Escandon, Enrique, Hall, Brian, Ray, Kallol, Walji, Abbas, O’Neil, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817756/ https://www.ncbi.nlm.nih.gov/pubmed/31501275 http://dx.doi.org/10.1128/MCB.00248-19 |
Ejemplares similares
-
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
por: Massó-Vallés, Daniel, et al.
Publicado: (2020) -
The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy
por: Savino, Mauro, et al.
Publicado: (2011) -
Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2015) -
Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue
por: Beaulieu, Marie-Eve, et al.
Publicado: (2023) -
A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis
por: Ozsvari, Bela, et al.
Publicado: (2017)